JMJD7-PLA2G4B

Across TCGA pan-cancer cohorts, JMJD7-PLA2G4B Mutation is linked to patient survival in 9 of 34 cancer types, making it a survival-associated JMJD7-PLA2G4B data layer compared with 27 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher JMJD7-PLA2G4B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated JMJD7-PLA2G4B expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

HNSC, DLBC, and KIRC are the cancer types where JMJD7-PLA2G4B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	II,III,IV	0.002	0.757	<.001	30	view →
DLBC	OS	Median	All	0.053	0.936	<.001	12	view →
KIRC	OS	Median	All	0.245	0.630	.044	8	view →
ACC	DFS	Median	All	0.089	0.666	.017	6	view →
LUSC	DFS	Median	II,III,IV	0.139	0.663	.027	6	view →
PRAD	DFS	Median	All	0.085	0.774	.001	6	view →
UCEC	DFS	Median	All	0.958	0.627	.023	6	view →
LIHC	DFS	Median	II,III,IV	0.044	0.414	<.001	3	view →
SKCM	DFS	Median	III,IV	0.087	0.647	.013	3	view →

Pink = unfavorable, green = favorable. Showing the 9 strongest of 9 lineages.

JMJD7-PLA2G4B–HNSC (OS)

Open the HNSC breakdown →